Addressing the nation on Tuesday, Prime Minister Narendra Modi talked about traditional home remedies (like drinking warm water through the day and taking home-made immunity boosters).
He had earlier held a video conference with ayush practitioners. The task force has members from the department of biotechnology (DBT), Council of Scientific and Industrial Research (CSIR) and also ayush practitioners. It is deliberating on inter-drug reactions if a patient is administered an ayurvedic medicine to fight Covid-19 along with the regular allopathic therapy.
Speaking to Business Standard, ayush minister Shripad Y Naik said the ministry’s task force is scrutinising the proposals submitted by ayush practitioners. Then, it will send it to research organisations like the Indian Council of Medical Research (ICMR) that is working actively on the Covid crisis.
“The ICMR would then revert to the ministry with its opinion – whether or not to go ahead with the line of therapy. In China, they have used traditional medicines along with allopathic drugs. We are awaiting a final decision on this and can expect it within this month,” Naik said.
He felt that since there is no established vaccine available for the novel coronavirus, ayurveda can be useful even as a preventive measure.
Meanwhile, some states like Haryana, Kerala, Goa have already started using it as a preventive medicine along with regular allopathic medicines. Sources said that some government hospitals are also using it to treat asymptomatic patients and those under quarantine.
“Ayurvedic texts have talked about epidemics, ways to control them and also illnesses that have very similar symptoms that the novel Coronavirus has. While there has been no clinical study on coronavirus patients, these therapies have been tried and tested over centuries. A singular treatment line is unlikely as ayurveda is highly customised according to the person’s prakriti or nature,” said Partap Chauhan, founder director of Jiva Ayurveda.
His organisation, with over 500 doctors, consults around 8,000 patients every day across the globe. Chauhan claimed that he has been getting distress calls from New York, where citizens want to know about simple home remedies they can adopt to stay safe.
In the first week of April, the Kerala government decided to use ayurveda to mitigate the spread of Covid. It classified people into seven categories for the purpose of administering medicines. Kerala chief minister has already said that Ayur Raksha clinics would be started at ayurveda dispensaries and hospitals. Even those recovering from Covid-19 would be given ayurvedic therapy to restore health.
The task force, too, is working on multiple protocols to be recommended for different groups of people having various underlying illnesses.
The industry feels that production of medicines, according to the protocol, would not be an uphill task as raw material is easily available and there are enough manufacturers in the country. Chandubhai Bhanushali, owner of Ayurchem and also the president of the Ayurvedic Drug Manufacturers Association (ADMA), that is affiliated to the CII, said that there are 9,500 ayurvedic companies in the country. Of this, only about 2 per cent are large firms like Baidyanath, Emami or Dabur.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)